OrgaNova TRiCBiO Announces Strategic Partnership with Eli Lilly

OrgaNova TRiCBiO announced a strategic partnership with Eli Lilly and Company, one of the world's leading pharmaceutical companies, to apply the ALI-PDO™ Organoid 2.0 platform to support Lilly's oncology drug development pipeline.

Under the agreement, OrgaNova TRiCBiO will leverage its biobank of over 1,500 patient-derived organoid models and its proprietary ALI-PDO™ technology to provide clinically predictive preclinical data supporting multiple oncology programs at Lilly.

"This partnership with Eli Lilly validates what we have believed from the beginning: that the industry needs a fundamentally better preclinical model," said Mohan Thiruvazhi, PhD, VP of Business Development. "We are proud to be partnering with one of the world's most innovative pharmaceutical companies."

Financial terms of the partnership were not disclosed.